MARKET

NEO

NEO

Neogenomics Inc
NASDAQ
15.72
+0.52
+3.42%
After Hours: 15.74 +0.02 +0.13% 19:27 03/28 EDT
OPEN
15.14
PREV CLOSE
15.20
HIGH
15.91
LOW
15.09
VOLUME
654.43K
TURNOVER
0
52 WEEK HIGH
21.22
52 WEEK LOW
11.03
MARKET CAP
2.01B
P/E (TTM)
-22.4283
1D
5D
1M
3M
1Y
5Y
NeoGenomics Showcases Commitment to Transforming Cancer Patient Care at AACR 2024 Annual Meeting
NeoGenomics will present key findings from 11 abstracts at the American Association for Cancer Research's 2024 Annual Meeting in San Diego. The company is a leading oncology testing services company. NeoGenomics is focused on transforming cancer care through innovation, precision, and compassion.
Barchart · 2d ago
Weekly Report: what happened at NEO last week (0318-0322)?
Weekly Report · 4d ago
All You Need to Know About NeoGenomics (NEO) Rating Upgrade to Buy
NASDAQ · 03/20 16:00
Does NeoGenomics (NEO) Have the Potential to Rally 43.34% as Wall Street Analysts Expect?
NASDAQ · 03/20 13:55
NeoGenomics Releases Inaugural Environmental, Social, and Governance (ESG) Report
NeoGenomics, Inc. Released its 2023 Environmental, Social, and Governance Report. The report highlights progress toward building a more sustainable, diverse, and equitable company. In 2023, women comprised 59.9% of the global workforce. The company recycled 310 tons of waste from its labs in 2023.
Barchart · 03/20 06:00
Commit To Purchase NeoGenomics At $10, Earn 9.1% Annualized Using Options
NASDAQ · 03/19 15:57
What 6 Analyst Ratings Have To Say About NeoGenomics
NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the U.S. And Switzerland. The company has an average 12-month price target of $20.67. NeoGenomics has an impressive revenue growth rate of 12.15%. Six analysts have provided ratings for the company in the latest quarter.
Benzinga · 03/18 18:00
Weekly Report: what happened at NEO last week (0311-0315)?
Weekly Report · 03/18 11:15
More
About NEO
NeoGenomics, Inc. provides a range of oncology diagnostic testing and consultative services which includes technical laboratory services. The Company offers professional interpretation of laboratory test results by licensed physicians who specialize in pathology and oncology. Its segments include Clinical Services and Advanced Diagnostics. The Clinical Services segment consists of clinical cancer testing; interpretation and consultative services; molecular and NGS testing, and comprehensive technical and professional services offering. Its Clinical Services customers include community-based pathology and oncology practices, hospital pathology labs, reference labs, and academic centers. The Advanced Diagnostics segment consist of clinical trials and research, validation laboratory services, and informatics. Its Advanced Diagnostics customers include pharmaceutical companies to whom it provides testing and other services to support their research studies and clinical trials.

Webull offers NeoGenomics, Inc. stock information, including NASDAQ: NEO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NEO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NEO stock methods without spending real money on the virtual paper trading platform.